Assay Method to Predict Sensitivity of Cancer Cell to Anticancer Drug
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Nov 13, 2008
app pub date -
Feb 4, 2005
filing date -
Feb 6, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
If a cancer cell sampled from a cancer patient by biopsy or the like can be examined with respect to its expressed molecules to evaluate sensitivity of the cancer cell to the present compound, the present compound can be selectively administered only to the cancer patient who is expected to benefit from antitumor activity of the present compound, thereby to enhance the therapeutic effect and reduce unnecessary adverse effects. Specifically, the characteristics of a cancer cell with respect to 'low level expression of pRB', 'positive expression of p16' and 'high level expression of cyclin E' are demonstrated to be useful as markers for sensitivity of the cancer cell to the present compound. Therefore, these characteristics of a cancer cell can be examined to evaluate previously sensitivity of the cancer cell to the present compound.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully